Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BBIO - BridgeBio Pharma, Inc.

IEX Last Trade
27.96
0.330   1.180%

Share volume: 16,124
Last Updated: Fri 27 Dec 2024 06:30:23 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.40%

PREVIOUS CLOSE
CHG
CHG%
$27.63
0.33
1.19%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
31%
Profitability 37%
Dept financing 25%
Liquidity 73%
Performance 16%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.74%
1 Month
7.90%
3 Months
16.54%
6 Months
21.10%
1 Year
-32.06%
2 Year
262.06%
Key data
Stock price
$27.96
P/E Ratio 
-11.54
DAY RANGE
$27.60 - $28.80
EPS 
-$2.58
52 WEEK RANGE
$22.94 - $41.80
52 WEEK CHANGE
-$31.76
MARKET CAP 
5.237 B
YIELD 
N/A
SHARES OUTSTANDING 
188.033 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.88
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,174,069
AVERAGE 30 VOLUME 
$1,987,342
Company detail
CEO: Neil Kumar
Region: US
Website: bridgebio.com
Employees: 400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.

Recent news